Dose dependant least neurotoxicity is found in

i.e. (Bleomycin): (527-H17th)DOXORUBICIN (525-H17th)* Predictable myelosuppression* Alopecia, nausea, mucositis* Cardiotoxicy in the form of atrial and ventricular dysarrhythmias* Powerful vesicant with necrosis of tissue apparent 4-7 days after an extravasation* Dexrazoxane is an antidote to doxorubicin-induced extravasationBLEOMYCIN (Antibiotics) (525-H17th)* Fever and chills, facial flush, and Raynaud's phenomenon* Hypertension, anaphylaxis* Pulmonary fibrosis * ** Little myelosuppressionCISPLATIN - (524-H17th)* Renal impairment is common*** Hypomagnesemia, hypocalcemia and tetany** Neurotoxicity with stocking and glove sensory motor neuropathy**** Hearing loss (50%)** Highly emetic drugs * ** Myelosuppression is less* Chronic vascular toxicity (Raynaud's phenomenon, Coronary artery disease) is a more unusual toxicity* Cisplatin is accumulated by proximal tubular cells where it induces mitochondrial injury and causes apoptosis and necrosis of renal tubular cells - ARF* Cisplatin is mutagenic, teratogenic and carcinogenic - Secondary leukemias are reported with the use of cisplatin and the use of cisplatin or carbolatin based chemotherapy for women with ovarian cancer is associated with a fourfold increased risks of developing secondary leukemia (1433-Goodman Gilman 10th)* Cisplatin has been associated with the development of AML usually 4 years or more after treatment -Lawrence